EGFR and lung adenocarcinoma: This is even more clinically relevant since recent studies demonstrated a significant therapeutic benefit of trastuzumab (an anti-ERBB2 mAb) and of newer TKIs, such as afatinib and neratinib, which target both EGFR and ERBB2, in selected patients with lung adenocarcinoma [38, 42–46].